What Стрезам Treats: Main Uses and Benefits

The core purpose of Стрезам (Etifoxine) is providing supportive symptomatic relief in situations involving certain distressing symptoms. The medication is commonly used within a therapeutic focus appropriate for these conditions. This supportive action is often relevant for patient groups where preserving functional stability and avoiding pronounced sedation are key clinical considerations.

The medication is primarily used in the symptomatic management of anxiety disorders and adjustment disorders characterized by emotional distress. It helps address symptom clusters that may become intense or disruptive, such as excessive worry, heightened agitation, and generalized emotional tension. The therapeutic approach is also relevant for easing symptoms related to heightened physiological activity like muscle tightness and functional strain.

Applied during phases of increased distress or discomfort, the medication supports patients by easing the overall symptom load and may help them cope more steadily with these difficult episodes. The overall aim of symptomatic management is to provide a baseline of support when symptoms interfere with daily comfort.

Quick Fact: Relief for Nervous Tension
Стрезам is commonly used when psychological and physical tension cluster together, particularly in conditions involving episodic or fluctuating manifestations.

Who Can and Cannot Use Стрезам (Etifoxine)

Official regulatory documents define strict population eligibility criteria for the use of Стрезам (Etifoxine), focusing on absolute contraindications and mandatory restrictions.

Contraindicated and Restricted Populations

Category	Regulatory Status
Absolute Contraindications	Contraindicated in patients with circulatory shock, myasthenia gravis, severe respiratory failure, or a known hypersensitivity to etifoxine. Use is also prohibited for patients with a documented history of severe liver problems or severe skin reactions (e.g., DRESS, SJS) related to prior Etifoxine treatment.
Organ Function	Contraindicated for patients with severely impaired liver function or severely impaired kidney function.
Formulation Restrictions	Contraindicated for patients with specific metabolic disorders like galactosemia or lactase deficiency due to the presence of lactose in the formulation.
Age Restriction	Not recommended for children and adolescents under 18 years of age. Safety and efficacy are not established in children below 15 years of age.
Pregnancy/Lactation	Not recommended during both pregnancy and breastfeeding.

Conditional Use

Specific populations require mandatory checks before treatment can begin. Patients identified as being at risk of hepatic disorders (e.g., older adults) must undergo baseline and follow-up liver function testing as a condition for treatment.

The official regulatory documents define the interaction profile of Etifoxine primarily through the principle of pharmacodynamic reinforcement. The profile is characterized by a mandated caution against co-administration with other substances that also depress the central nervous system ( CNS). Combining these substances is officially documented to increase the overall central depressant effect.

The CNS depressant categories cited in the regulatory labeling that carry this risk include central analgesics, antipsychotics, sedative antihistamines, benzodiazepines, hypnotic medicines, and certain antidepressants.

Interaction Category	Effect Documented in Regulatory Labels
CNS Depressants	Increased depressant effects (additive risk)
Alcohol	Increases the sedative effect of Etifoxine

A specific substance restriction exists for alcohol. Co-ingestion of alcohol or alcohol-containing medicines is cautioned against due to the risk of amplifying the sedative properties. This substance-specific warning aligns with the overall pharmacodynamic focus of the interaction profile.

No drug-drug combinations are formally classified as contraindicated based solely on interaction risk. Furthermore, official labels do not document any specific pharmacokinetic interactions, such as those involving Cytochrome P450 ( CYP) enzymes or drug transporters, nor do they specify mandatory timing separation rules between doses. The documented interaction structure is defined exclusively by the need for caution against additive CNS depression.

The mechanism of action for Стрезам ( Etifoxine) is distinct, relying on a dual pharmacodynamic profile to enhance the central nervous system's ( CNS) inhibitory signaling.

Direct Potentiation of GABA-A Receptors

This domain covers the molecule's ability to act as a Positive Allosteric Modulator at the GABA-A receptor, binding to a unique site separate from the classical benzodiazepine site. This interaction enhances the effect of GABA, leading to an immediate increase in chloride ion influx, which directly reduces the excitability of nerve cells and initiates a rapid change toward a reduced state of neuronal excitability.

Activation of Endogenous Neurosteroid Synthesis

The second pathway involves TSPO (18 kDa Translocator Protein) agonism, which facilitates the transport of cholesterol, the precursor for neurosteroids like allopregnanolone ( ALLO). Increased ALLO synthesis provides a strong, sustained reinforcement of GABA-A receptor function, contributing to the suppression of neuronal activity. This indirect modulation contributes to the modulation and maintenance of CNS inhibitory tone.

These two mechanisms operate concurrently, resulting in a comprehensive and sustained modulation of CNS pathways.

Official Administration Guidelines for Стрезам

Стрезам (Etifoxine hydrochloride) is strictly administered via the oral route as a 50 mg hard capsule. The standard approach to its use is governed by specific instructions concerning dosage, frequency, and treatment duration.

---

Dosing and Scheduling

The typical daily dosage for adults ranges from 150 mg to 200 mg. To achieve this, the total daily amount is divided and taken in two to three separate doses throughout the day. The capsules should be swallowed with a small amount of water.

Treatment with the medicine is defined as a short-to-medium-term course. The duration of use is usually a few days to a few weeks, and generally may not exceed 8 weeks, though some clinical guidelines cite a maximum duration of 12 weeks for certain regimens.

---

Procedural Constraints and Age Groups

If a dose is missed, standard instructions indicate that the subsequent dose should not be increased to compensate. This instruction maintains consistency in the prescribed schedule.

Regarding the pediatric population, the medicine is not recommended for use in children and adolescents, as its safety and efficacy have not been formally established in patients under 18 years of age. For adult patients with risk factors for liver issues, usage instructions note that liver function tests should be conducted before treatment initiation and approximately one month afterward.

Research Evidence: Overview of Studies for Стрезам (Etifoxine)

---

Evidence for Use in Adjustment Disorder with Anxiety (ADWA)

Clinical evaluation for Etifoxine has primarily involved short-term randomized controlled trials (RCTs) in adult outpatients with Adjustment Disorder with Anxiety. This type of research is relevant in trials assessing short-term or episodic symptom patterns, with studies conducted during periods of increased symptom activity. Researchers monitored responses over defined time intervals, usually 4 to 12 weeks. Outcomes describing episodic or acute changes were monitored using standardized tools, like the Hamilton Anxiety Rating Scale (HAM-A), relevant in evidence describing how symptoms are measured.

Many studies explored how symptoms evolved in the observed populations. Some comparative studies described patterns where the measurements of anxiety severity were recorded for both Etifoxine and reference medications, specifically some benzodiazepines and buspirone. Findings help contextualize how patients reported their experience during the short period of observation. However, the findings across all studies for this primary evaluation were mixed. While some studies reported changes measured during the study period compared to a placebo, a major regulatory review noted that results in other placebo-controlled trials were inconsistent. This indicates that evidence quality varies across studies, and findings suggest patterns of symptom change that were not uniform across all studies.

---

Evidence in Special Populations and Functional Measures

Beyond the core studies for adjustment disorder, research has explored the effects of Etifoxine in specific, narrow patient groups, particularly older adults. In controlled studies involving healthy elderly volunteers, researchers examined temporary physiological imbalance, specifically focusing on vigilance and psychomotor performance—outcomes reflecting daily functioning or activity level. Measurements of vigilance and psychomotor performance were recorded, and studies reported less change in these measures for Etifoxine when evaluated alongside known sedating agents.

Further, Etifoxine was evaluated in research exploring symptoms in patients whose conditions are marked by functional limitations, such as those with drug-resistant epilepsy. These exploratory studies monitored physiological strain or stress, focusing on specific anxiety symptom subtypes in these populations. Research provides context on these small, specialized groups but research does not determine whether an individual in a similar situation will respond similarly.

---

Long-Term Studies and Follow-up

The available research has focused on short-term symptom changes. Follow-up durations were limited in most primary clinical trials to typically 4 to 12 weeks. Consequently, there is limited information for long-term outcomes, and the long-term effects are not fully established. Long-term data regarding the durability of any observed patterns and the patient experience over extended periods are not well characterized by the existing studies.

Key Studies & References

1. Etifoxine versus alprazolam for the treatment of adjustment disorder with anxiety: a randomized controlled trial
2. Etifoxine impairs neither alertness nor cognitive functions of the elderly: A randomized, double-blind, placebo-controlled crossover study

Common questions about Стрезам (FAQ)

Q: How quickly should someone expect to feel the effects of Стрезам?

Official regulatory data describes how quickly the medicine enters the bloodstream after administration. The active substance is rapidly absorbed after being swallowed, with peak levels typically reached in the blood within two to three hours. This information relates to the drug's presence in the body, and the full therapeutic effect may be experienced differently by each patient.

Q: Do studies suggest Стрезам helps with sleep difficulties related to anxiety?

The drug is officially indicated for anxiety symptoms associated with adjustment disorder. Since emotional tension can often interfere with sleep, the anxiolytic effect may help address the emotional tension that can interfere with sleep. However, the medicine is not formally listed as a primary treatment for sleep difficulties alone.

Q: Is there a risk of withdrawal symptoms when stopping Стрезам?

The potential for dependence and withdrawal is addressed in official safety reviews, which note the drug is classified as a non-benzodiazepine anxiolytic. Nonetheless, dependence and withdrawal risks are recognized. Regulatory information notes that the medicine should not be discontinued suddenly.

Q: Are there any specific foods to avoid while on Стрезам?

Official information does not list any specific foods that must be avoided while using this medicine. Official summaries caution against the concomitant use of alcohol due to the potential for increased sedative effects.

Q: Can Стрезам affect my ability to drive or operate machinery?

Yes, official product information includes warnings regarding operating vehicles and machinery. Official regulatory warnings indicate that driving or operating machinery should be avoided, particularly when starting treatment, due to the risk of side effects like slight drowsiness and dizziness.

Q: Is the mechanism of action of Стрезам fully understood by researchers?

The core mechanism of the drug, involving two distinct actions on brain signaling, is well-documented. While these actions are the focus of current understanding, official summaries sometimes note that the exact way the drug works may still be subject to ongoing research.

Q: Does research indicate any benefits of Стрезам beyond anxiety relief?

According to regulatory summaries, the official approved use is strictly limited to the short-term management of adjustment disorder with anxiety. Any other potential effects, such as pain relief or neuroprotection, have mainly been explored in initial studies and are not part of the licensed therapeutic use of the medicine.

Q: Is Стрезам excreted in breast milk?

Official information does not explicitly confirm whether the medicine passes into breast milk. However, due to potential risks to the infant, official regulatory documents state that the use of the drug is explicitly not recommended during breastfeeding.

Q: Is it normal to feel dizzy or lightheaded while taking Стрезам?

Yes, official adverse event reports from regulatory bodies list dizziness as a possible side effect of this medicine. Official warnings indicate that the risk of dizziness means caution should be exercised with activities that require alertness, such as driving or operating machinery.

Q: What happens if Стрезам is taken at the same time as cold or flu medicine?

Regulatory safety warnings require caution if the cold or flu medicine contains an ingredient that depresses the Central Nervous System (CNS). Examples of such ingredients are certain types of antihistamines or central pain relievers. Official information advises caution for such combinations, as they may increase the overall sedative effect.

Q: Is it possible for Стрезам to interact with contraception medication?

Official safety reviews have reported a risk of unexpected bleeding between periods (metrorrhagia) in women who are also using oral contraceptives. Although formal human studies on direct interaction were not required, this specific event is noted in regulatory documents as a potential safety concern.

Q: Do official patient information leaflets mention anything about taking Стрезам with food?

Some official patient information leaflets specifically suggest taking the capsule with food. Regulatory information consistently describes the administration of the capsule as being swallowed with a small amount of water.

How to Store and Dispose of Stresam (Etifoxine Hydrochloride)

Storage and disposal of Stresam must strictly follow conditions documented in official regulatory labeling to ensure product stability and environmental safety.

Required Storage Conditions

Condition	Requirement
Temperature	Store at or below 25 C (25 degrees Celsius).
Protection	Keep the capsules in the original carton and blister packaging to protect them from light and moisture.
Safety	The product must be kept out of the sight and reach of children.
Stability	The medicine must not be used after the expiry date printed on the carton.

Disposal Instructions

Unused or expired Stresam must not be disposed of in drains or sewerage systems (wastewater) or in regular household trash. The official instruction requires that all unused medicine should be returned to a pharmacist or designated collection point for environmentally sound disposal in accordance with local regulations.